Clinical Trial

FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

Study acronym: FUNCtion ALS
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection). The trial will also assess how the body processes the drug and whether it shows early signs of benefit over 24 weeks.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-06
Trial Details
NCT Number NCT07674667
Lead Sponsor Trace Neuroscience, Inc.
Conditions Amyotrophic Lateral Sclerosis
Enrollment 30 participants
Start Date 2026-08
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-05